Immunotherapy combo increases progression-free survival in advanced melanoma patients

(Memorial Sloan Kettering Cancer Center) Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center simultaneously presented today at the 2015 American Society of Clinical Oncology annual meeting and published online in the New England Journal of Medicine.